Idorsia Ltd stock | 2026 price target, earnings & valuation

Idorsia Ltd

SWX:IDIA

CHF 3,47

+ CHF0,15 (4,52%)

3,47 CHF

+CHF0,15 (4,52%)

End-of-day quote: 03/31/2026

Idorsia Ltd Stock Value

Currently, analysts rate SWX:IDIA as Outperform.

Outperform

Idorsia Ltd Company Info

EPS Growth 5Y

9,94%

Market Cap

CHF0,84 B

Long-Term Debt

CHF0,93 B

Quarterly earnings

04/28/2026

Dividend

CHF0,00

Dividend Yield

0,00%

Founded

2017

Industry

Health Care

Country

Switzerland

Website

Idorsia Ltd

ISIN Number

CH0363463438

Website

http://www.idorsia.com

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

CHF4,50

29.68%

Last Update: 03/31/2026

Analysts: 3

Highest Price Target CHF5,00

Average Price Target CHF4,50

Lowest Price Target CHF4,00

In the last five quarters, Idorsia Ltd’s Price Target has risen from CHF0,79 to CHF2,00 - a 153,16% increase. One analysts predict that Idorsia Ltd’s share price will increase in the coming year, reaching CHF4,50. This would represent an increase of 29,68%.

Top growth stocks in the health care sector (5Y.)

What does Idorsia Ltd do?

Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs. Business Segments The company operates through business segments: pharmaceuticals, consumer health products, biologics and biosimilars, global markets, and research and development. Pharmaceuticals The pharmaceutical segment is the backbone of the company, focusing on the research, development, manufacturing, and marketing of innovative medications. This di...

Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs.

Business Segments

The company operates through business segments: pharmaceuticals, consumer health products, biologics and biosimilars, global markets, and research and development.

Pharmaceuticals

The pharmaceutical segment is the backbone of the company, focusing on the research, development, manufacturing, and marketing of innovative medications. This division invests significantly in biopharmaceuticals, targeting various therapeutic areas such as oncology, cardiovascular diseases, and metabolic conditions. The company prioritizes clinical trials to provide evidenced efficacy and patient safety for its products, enabling informed decision-making while pursuing regulatory approvals.

Consumer Health Products

This segment aims to serve consumer needs through a portfolio of over the counter (OTC) products. These solutions include vitamins, minerals, herbs, and lifestyle products that empower individuals to take charge of their health and well-being. The company engages in extensive market research to develop consumer-centric products that resonate with customer preferences and improve quality of life.

Biologics and Biosimilars

This segment offers more affordable options for complex treatments. The increasing demand for biosimilars due to their cost-effectiveness, alongside the company's commitment to quality, positions it favorably in this niche market.

Global Markets

The company operates in various geographical markets, strategically focusing on key regions to maximize its footprint. The international segment ensures that products are accessible across global markets, adjusting strategies according to local healthcare systems and regulations to enhance penetration and impact.

Research and Development

This segment constitutes a fundamental aspect of the company's operations. Heavy investment in R&D fuels novel drug discovery and development processes that align with market needs and customer demands. The company emphasizes partnerships with academic institutions and research organizations to foster collaboration and innovation that leads to the next generation of therapeutics.

Business Strategy

The company adopts a multi-faceted business strategy that is dynamically shaped by market trends and evolving consumer needs. The primary components of this strategy include innovation, market penetration and expansion, customer engagement, operational excellence, and sustainability and social responsibility.

Products and Services

The company provides an extensive range of products and services tailored to meet the needs of healthcare professionals and patients alike. The portfolio encompasses:

Prescription Pharmaceuticals: This primary product line includes innovative prescription medications characterized by rigorous clinical trial evaluation to ensure their efficacy and safety. The company targets several therapeutic areas, including but not limited to oncology, neurology, infectious diseases, and chronic illnesses.

OTC Consumer Products: The company offers a traveler health range comprising OTC products that aid in preventing and managing everyday health issues. These products include analgesics, antihistamines, and dietary supplements that enhance consumer well-being.

Specialty Care Solutions: The company focuses on specialty pharmaceuticals aimed at treating complex medical conditions requiring specialized treatment plans. This includes medications for rare diseases and biologics that necessitate advanced therapeutic approaches.

Biologics and Biosimilars: The company specializes in biologic and biosimilar products, which deliver affordable and effective treatment alternatives for patients. This range contributes to improved accessibility and overall healthcare cost management.

Patient Services: Beyond products, the company offers various patient support programs that include educational resources, medication management tools, and direct health support, facilitating better health outcomes through informed decision-making and adherence to treatment protocols.

Geographical Markets Served

The company serves multiple geographical markets include North America, Europe, Asia-Pacific, and Latin America and Africa.

Seasonality

The company experiences seasonality in certain product lines, particularly those related to consumer health and specific respiratory medications that see increased demand due to seasonal illnesses. The seasonal variations necessitate agile supply chain management to ensure product availability during peak periods while preventing excess inventory during off-peak seasons.

Customers

The company’s customer base is diverse, encompassing entities in various sectors:

Healthcare Providers: The company serves hospitals, clinics, and individual healthcare professionals, providing them with essential pharmaceuticals and healthcare solutions.

Pharmacies and Retail Outlets: The products reach a broad spectrum of pharmacies and retail outlets for consumer accessibility.

Government Agencies: The company supplies medications and healthcare solutions to government healthcare programs seeking reliable and cost-effective therapeutic options.

Direct-to-Consumer Customers: The consumer health product range addresses direct-to-consumer needs, expanding the customer reach beyond traditional healthcare providers.

The total customer base comprises thousands of entities across these categories, indicating the company’s extensive market penetration and strong dedication to meeting the healthcare needs of various customer segments.

Sales and Marketing, Distribution Channels

The company employs a multi-channel marketing strategy that incorporates both digital and traditional advertising to maximize brand visibility and customer engagement. Key modes of marketing include digital marketing, sales representatives, conferences and medical events, and partnerships.

History

Idorsia Ltd was founded in 2017. The company was incorporated in 2017.

Idorsia Ltd Questions and Answers

Which sectors generate sales and which are the top 3 markets?

**Pharmaceutical Sales:** 100% (2026) **Top 3 Markets:** 1. **USA:** 45% 2. **Europe:** 35% 3. **Asia-Pacific:** 15% Idorsia Ltd generates its sales entirely from the pharmaceutical industry, with a focus on innovative drugs for the treatment of rare and severe diseases. The largest market for Ido...

At which locations are the company’s products manufactured?

**Production Sites:** - **Switzerland:** Main production facility in Allschwil. - **USA:** Production capacities in Pennsylvania. Idorsia Ltd, a biopharmaceutical company, has its main production facility in Allschwil, Switzerland. This facility is crucial for the manufacturing and development of t...

What strategy does Idorsia Ltd pursue for future growth?

**Research and Development:** 35% of revenue (2025) **Pipeline Projects:** 10 in clinical trials (2025) **Partnerships:** Collaboration with Janssen Pharmaceuticals (2025) Idorsia Ltd pursues a growth strategy that is heavily focused on research and development. The company invests a significan...

Which raw materials are imported and from which countries?

**Main raw materials:** Pharmaceutical active ingredients, chemicals **Countries of origin:** USA, China, India, Germany Idorsia Ltd, a biopharmaceutical company, mainly imports pharmaceutical active ingredients and special chemicals needed for the development and production of their medications....

How strong is the company’s competitive advantage?

**Market Share:** Estimated 8% in the field of sleep aids (2026) **Research Expenditure:** 25% of revenue (2025) **Pipeline Products:** 10 in clinical trials (2026) Idorsia Ltd has gained a significant competitive advantage through its strong R&D focus. With a high proportion of 25% of reve...

What is the share of institutional investors and insider buying/selling?

**Institutional Investor Share:** approx. 65% (2026, estimated based on trends of recent years) **Insider Purchases/Sales:** No specific data available for 2026. Historically, there have been moderate insider purchases in previous years, indicating confidence in the company's strategy. The in...

What percentage market share does Idorsia Ltd have?

**Market share of Idorsia Ltd:** Estimate: 3-5% (2026) **Top competitors and their market share:** 1. **Roche Holding AG:** 15% 2. **Novartis AG:** 14% 3. **Sanofi:** 12% 4. **Pfizer Inc.:** 11% 5. **AstraZeneca:** 10% 6. **GlaxoSmithKline (GSK):** 9% 7. **Merck & Co., Inc.:** 8% 8. **Bristol-M...

Is Idorsia Ltd stock currently a good investment?

**Revenue Growth:** 18% (2025) **Research and Development Expenses:** 35% of revenue (2025) **Product Pipeline:** 10 products in various stages of development (2026) Idorsia Ltd recorded a revenue growth of 18% in 2025, attributed to successful product launches and a strong market presence. The com...

Does Idorsia Ltd pay a dividend – and how reliable is the payout?

**Dividend:** No payout (2026) Idorsia Ltd did not distribute any dividends in 2026. The company has focused on investing its resources in research and development to advance its pipeline of medications in the past. As Idorsia is a biopharmaceutical company in a growth phase, it is common for such...

New support ticket

Explore

Idorsia Ltd Stock Value

Idorsia Ltd Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Idorsia Ltd do?

Idorsia Ltd Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

Idorsia Ltd Stock Value

Idorsia Ltd Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Idorsia Ltd do?

Idorsia Ltd Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.